The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs

Acta Oncol. 1992;31(2):115-23. doi: 10.3109/02841869209088890.

Abstract

Many breast tumors appear to follow a predictable clinical pattern, being initially responsive to endocrine therapy and to cytotoxic chemotherapy but ultimately exhibiting a phenotype resistant to both modalities. Using the MCF-7 human breast cancer cell line as an example of an 'early' phenotype (estrogen and progesterone receptor positive, steroid responsive, low metastatic potential), we have isolated and characterized a series of hormone-independent but hormone-responsive variants (MIII and MCF7/LCC1). However, these variants remain responsive to both antiestrogens and cytotoxic drugs (methotrexate and colchicine). MIII and MCF7/LCC1 cells appear to mimic some of the critical aspects of the early progression to a more aggressive phenotype. An examination of the phenotype of these cells suggests that some hormone-independent breast cancer cells are derived from hormone-dependent parental cells. The development of a hormone-independent phenotype can arise independently of acquisition of a cytotoxic drug resistant phenotype.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / etiology
  • Breast Neoplasms* / pathology
  • Colchicine / pharmacology
  • Drug Resistance*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Methotrexate / pharmacology
  • Mice
  • Mice, Nude
  • Models, Biological
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / physiopathology
  • Phenotype
  • Tumor Cells, Cultured

Substances

  • Colchicine
  • Methotrexate